Genentech to restrict Avastin availability due to off-label use

10/11/2007 | Wall Street Journal, The · NYTimes.com

Genentech said it will halt the distribution of its cancer treatment Avastin to compounding pharmacies as more ophthalmologists recommend the drug's off-label use for wet age-related macular degeneration. The move is an attempt to promote Genentech's more-expensive eye drug Lucentis, which has lagged in sales, but Medicare says limiting distribution of the cancer drug could cost the system as much as $3 billion a year.

View Full Article in:

Wall Street Journal, The · NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President, Science and Regulatory Affairs
American Beverage Association
Washington, DC
Senior Manager of Medical Management
Network Health
Medford, MA
MEDICAL SCIENCE LIAISON - 14000002RO
Abbott
Columbus, OH
Manager, Medical Management
Network Health
Medford, MA
Executive Medical Director
Aspirus Network Inc
Wausau, WI